Alector reports Q4 2022 net loss of $52.4M; cash runway through 2025

Alector, Inc.

2022-FY EPS reported -$1.62 revenue$133,600,000

Net loss Q4 2022: $52.4M ($0.63/share) vs $55.6M ($0.68) in Q4 2021; full-year net loss $133.3M ($1.62) vs $36.3M ($0.45).
Cash, cash equivalents, investments $712.9M as of Dec 31, 2022; management expects runway through 2025.
2023 guidance: collaboration revenue $15-25M, R&D expenses $225-245M, G&A expenses $60-70M.
INVOKE-2 Phase 2 enrollment completion expected Q3 2023, data by Q4 2024; $17.8M milestone from AbbVie triggered.
INFRONT-3 pivotal trial for latozinemab: regulatory engagement mid-2023, data readout early 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alector, Inc. reported financial results for the quarter ended December 31, 2022.

Period: the quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.